Advocacy intelligence hub — real-time data for patient organizations
City of Hope Medical Center — PHASE1
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
National Heart, Lung, and Blood Institute (NHLBI) — PHASE2
Eltrombopag: FDA approved
PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.
National Heart, Lung, and Blood Institute (NHLBI) — PHASE2
National Heart, Lung, and Blood Institute (NHLBI) — PHASE1
National Heart, Lung, and Blood Institute (NHLBI) — PHASE2
National Heart, Lung, and Blood Institute (NHLBI) — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
ELTROMBOPAG
Dr. Reddy's Laboratories Inc.,
Eltrombopag
(ELTROMBOPAG OLAMINE)Orphan drugNovadoz Pharmaceuticals LLC
ELTROMBOPAG
(ELTROMBOPAG)standardDr. Reddy's Laboratories Inc.,
12.1 Mechanism of Action Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as c...
Omisirge
(OMIDUBICEL-ONLV)Orphan drugstandardGamida Cell Inc.
12.1 Mechanism of Action OMISIRGE is a nicotinamide (NAM) modified allogeneic hematopoietic progenitor cell therapy derived from cord blood used as an...
Huang Jinbo, MD.
Chinese Academy of Medical Sciences
📍 Tianjin, Tianjin Municipality
Jun Shi, PhD
Regenerative Medicine Center and Red Blood Cell Disorders Center
📍 Tianjin, Tianjin Municipality
Petros Kountouris, PhD
Cyprus Institute of Neurology and Genetics (CING)
Emma M Groarke, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
📍 Bethesda, Maryland
Ryotaro Nakamura
City of Hope Medical Center
📍 Duarte, California
Béatrice Gulbis, MD
Hôpital ERASME (ERASME)